Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP05 vs EU-approved Lucentis in Wet Age-Related Macular Degeneration
2023-507459-31-03Phase 3Completed
- Sponsor
- CuraTeQ Biologics
- Start
- May 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of ranibizumab in exudative macular degeneration (2 arms), sponsored by CuraTeQ Biologics. Primary endpoint: Change in BCVA letters at Week 8 vs baseline. Started May 2024; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2023-507459-31-03.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507459-31-03.